|
1
|
Palumbo A and Anderson K: Multiple
myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kyle RA, Gertz MA, Witzig TE, Lust JA,
Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson
DR, et al: Review of 1027 patients with newly diagnosed multiple
myeloma. Mayo Clin Proc. 78:21–33. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cao B, Li J and Mao X: Dissecting
bortezomib: Development, application, adverse effects and future
direction. Curr Pharm Des. 19:3190–3200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herndon TM, Deisseroth A, Kaminskas E,
Kane RC, Koti KM, Rothmann MD, Habtemariam B, Bullock J, Bray JD,
Hawes J, et al: U.S. Food and drug administration approval:
Carfilzomib for the treatment of multiple myeloma. Clin Cancer Res.
19:4559–4563. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang F, Zhang W, Guo L, Bao W, Jin N, Liu
R, Liu P, Wang Y, Guo Q and Chen B: Gambogic acid suppresses
hypoxia-induced hypoxia-inducible factor-1α/vascular endothelial
growth factor expression via inhibiting phosphatidylinositol
3-kinase/Akt/mammalian target protein of rapamycin pathway in
multiple myeloma cells. Cancer Sci. 105:1063–1070. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adachi M, Hoshino Y, Izumi Y, Sakai H and
Takagi S: Effects of inhibitors of vascular endothelial growth
factor receptor 2 and downstream pathways of receptor tyrosine
kinases involving phosphatidylinositol 3-kinase/Akt/mammalian
target of rapamycin or mitogen-activated protein kinase in canine
hemangiosarcoma cell lines. Can J Vet Res. 80:209–216.
2016.PubMed/NCBI
|
|
7
|
Cirstea D, Santo L, Hideshima T, Eda H,
Mishima Y, Nemani N, Mahindra A, Yee A, Gorgun G, Hu Y, et al:
Delineating the mTOR Kinase pathway using a dual TORC1/2 inhibitor,
AZD8055, in multiple myeloma. Mol Cancer Ther. 13:2489–2500. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gera J and Lichtenstein A: The mammalian
target of rapamycin pathway as a therapeutic target in multiple
myeloma. Leuk Lymphoma. 52:1857–1866. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dowling RJ, Topisirovic I, Fonseca BD and
Sonemberg N: Dissecting the role of mTOR: Lessons from mTOR
inhibitor. Biochim Biophys Acta. 1804:433–439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2010. View Article : Google Scholar
|
|
11
|
Hara K, Yonezawa K, Weng QP, Kozlowski MT,
Belham C and Avruch J: Amino acid sufficiency and mTOR regulate p70
S6 kinase and eIF-4E BP1 through a common effector mechanism. J
Biol Chem. 273:14484–14494. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Serrano M: Dissecting the role of mTOR
complexes in cellular senescence. Cell Cycle. 11:2231–2232. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lang SA, Hackl C, Moser C, Fichtner-Feigl
S, Koehl GE, Schlitt HJ, Geissler EK and Stoeltzing O: Implication
of RICTOR in the mTOR inhibitor-mediated induction of insulin-like
growth factor-I receptor (IGF-IR) and human epidermal growth factor
receptor-2 (Her2) expression in gastrointestinal cancer cells.
Biochim Biophys Acta. 1803:435–442. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wander SA, Hennessy BT and Slingerland JM:
Next-generation mTOR inhibitors in clinical oncology: How pathway
complexity informs therapeutic strategy. J Clin Invest.
121:1231–1241. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li J, Zhu J, Cao B and Mao X: The mTOR
signaling pathway is an emerging therapeutic target in multiple
myeloma. Curr Pharm Des. 20:125–135. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Willems L, Tamburini J, Chapuis N, Lacombe
C, Mayeux P and Bouscary D: PI3K and mTOR signaling pathways in
cancer: New data on targeted therapies. Curr Oncol Rep. 14:129–138.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benjamin D, Colombi M, Moroni C and Hall
MN: Rapamycin passes the torch: A new generation of mTOR
inhibitors. Nat Rev Drug Discov. 10:868–880. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feldman ME, Apsel B, Uotila A, Loewith R,
Knight ZA, Ruggero D and Shokat KM: Active-site inhibitors of mTOR
target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol.
7:e382009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu DM, Zhao L, Liu TT, Jiao PL, Zhao DD,
Shih MS, Tao B, Sun LH, Zhao HY and Liu JM: Rictor/mTORC2 loss in
osteoblasts impairs bone mass and strength. Bone. 90:50–58. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hsieh AC, Costa M, Zollo O, Davis C,
Feldman ME, Testa JR, Meyuhas O, Shokat KM and Ruggero D: Genetic
dissection of the oncogenic mTOR pathway reveals druggable
addiction to translational control via 4EBP-eIF4E. Cancer Cell.
17:249–261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yan H, Frost P, Shi Y, Hoang B, Sharma S,
Fisher M, Gera J and Lichtenstein A: Mechanism by which mammalian
target of rapamycin inhibitors sensitize multiple myeloma cells to
dexamethasone-induced apoptosis. Cancer Res. 66:2305–2313. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Francis LK, Alsayed Y, Leleu X, Jia X,
Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, et al:
Combination mammalian target of rapamycin inhibitor rapamycin and
HSP90 inhibitor 17-allylamino-17-demetoxiygeldanamycin has
synergistic activity in multiple myeloma. Clin Cancer Res.
12:6826–6835. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gupta SC, Kannappan R, Reuter S, Kim JH
and Aggarwal BB: Chemosensitization of tumors by resveratrol. Ann N
Y Acad Sci. 1215:150–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baur JA and Sinclair DA: Therapeutic
potential of resveratrol: The in vivo evidence. Nat Rev Drug
Discov. 5:493–506. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bishayee A: Cancer prevention and
treatment with resveratrol: From rodent studies to clinical trials.
Cancer Prev Res (Phila). 2:409–418. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bhardwaj A, Sethi G, Vadhan-Raj S,
Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S and Aggarwal
BB: Resveratrol inhibits proliferation, induces apoptosis, and
overcomes chemoresistance through down-regulation of STAT3 and
nuclear factor-kappaB-regulated antiapoptotic and cell survival
gene products in human multiple myeloma cells. Blood.
109:2293–2302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boissy P, Andersen TL, Abdallah BM, Kassem
M, Plesner T and Delaissé JM: Resveratrol inhibits myeloma cell
growth, prevents osteoclast formation, and promotes osteoblast
differentiation. Cancer Res. 65:9943–9952. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kueck A, Opipari AW Jr, Griffith K, Tan L,
Choi M, Huang J, Wahl H and Liu JR: Resveratrol inhibits glucose
metabolism in human ovarian cancer cells. Gynecol Oncol.
107:450–457. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Waite KA, Sinden MR and Eng C:
Phytoestrogen exposure elevates PTEN levels. Hum Mol Genet.
14:1457–1463. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He X, Wang Y, Zhu J, Orloff M and Eng C:
Resveratrol enhances the anti-tumor activity of the mTOR inhibitor
rapamycin in multiple breast cancer cell lines mainly by
suppressing rapamycin-induced AKT signaling. Cancer Lett.
301:168–176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sui T, Ma L, Bai X, Li Q and Xu X:
Resveratrol inhibits the phosphatidylinositide 3-kinase/protein
kinase B/mammalian target of rapamycin signaling pathway in the
human chronic myeloid leukemia K562 cell line. Oncol Lett.
7:2093–2098. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Copp J, Manning G and Hunter T:
TORC-specific phosphorylation of mammalian target of rapamycin
(mTOR): Phospho-Ser2481 is a marker for intact mTOR signaling
complex 2. Cancer Res. 69:1821–1827. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Raje N, Kumar S, Hideshima T, Ishitsuka K,
Chauhan D, Mitsiades C, Podar K, Le Gouill S, Richardson P, Munshi
NC, et al: Combination of the mTOR inhibitor rapamycin and CC-5013
has synergistic activity in multiple myeloma. Blood. 104:4188–4193.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cao Y, Fu ZD, Wang F, Liu HY and Han R:
Anti-angiogenic activity of resveratrol, a natural compound from
medicinal plants. J Asian Nat Prod Res. 7:205–213. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gusman J, Malonne H and Atassi G: A
reappraisal of the potential chemopreventive and chemotherapeutic
properties of resveratrol. Carcinogenesis. 22:1111–1117. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang B, Liu J and Gong Z: Resveratrol
induces apoptosis in K562 cells via the regulation of mitochondrial
signaling pathways. Int J Clin Exp Med. 8:16926–16933.
2015.PubMed/NCBI
|
|
38
|
Jang J, Jeong SJ, Kwon HY, Jung JH, Sohn
EJ, Lee HJ, Kim JH and Kim SH, Kim JH and Kim SH: Decursin and
doxorubicin are in synergy for the induction of apoptosis via STAT3
and/or mTOR pathways in human multiple myeloma cells. Evid Based
Complement Alternat Med. 2013:5063242013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Trung Quoc L, Espinoza JL, Takami A and
Nakao S: Resveratrol induces cell cycle arrest and apoptosis in
malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS One.
8:e551832013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen Q, Ganapathy S, Singh KP, Shankar S
and Srivastava RK: Resveratrol induces growth arrest and apoptosis
through activation of FOXO transcription factors in prostate cancer
cells. PLoS One. 5:e152882010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li H, Hu J, Wu S, Wang L, Cao X, Zhang X,
Dai B, Cao M, Shao R, Zhang R, et al: Auranofin-mediated inhibition
of PI3K/AKT/mTOR axis and anticancer activity in non-small cell
lung cancer cells. Oncotarget. 7:3548–3558. 2016.PubMed/NCBI
|
|
42
|
Que W, Chen J, Chuang M and Jiang D:
Knockdown of c-Met enhances sensitivity to bortezomib in human
multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
APMIS. 120:195–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Feng N, Luo J and Guo X: Silybin
suppresses cell proliferation and induces apoptosis of multiple
myeloma cells via the PI3K/Akt/mTOR signaling pathway. Mol Med Rep.
13:3243–3248. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rousseau D, Gingras AC, Pause A and
Sonenberg N: The eIF4E-binding proteins 1 and 2 are negative
regulators of cell growth. Oncogene. 13:2415–2420. 1996.PubMed/NCBI
|
|
45
|
Sarbassov DD, Ali SM, Kim DH, Guertin DA,
Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM: Rictor, a
novel binding partner of mTOR, defines a rapamycin-insensitive and
raptor-independent pathway that regulates the cytoskeleton. Curr
Biol. 14:1296–1302. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gera JF, Mellinghoff IK, Shi Y, Rettig MB,
Tran C, Hsu JH, Sawyers CL and Lichtenstein AK: AKT activity
determines sensitivity tomammalian target of rapamycin (mTOR)
inhibitors by regulating cyclin D1 and c-myc expression. J Biol
Chem. 279:2737–2746. 2004. View Article : Google Scholar : PubMed/NCBI
|
